The Hypersomnia Treatment market is projected to register a CAGR of 8.7% during the forecast period (2022 - 2027).
Since the COVID-19 pandemic, the proportion of sleeping disorder complaints has risen drastically. The sleep disorders were characterized as intrinsic (arising from the body), extrinsic (due to environmental conditions), or disturbances to circadian rhythm. The social isolation and interruption of daily routines during the COVID 19 lockdown have caused a rise in psychological stress among people, which in turn has increased sleep disorders all over the world. An article presented in the Journal of Clinical Sleep Medicine in February 2021 deduced that around 40% of the people from the general and health care populations had reported various sleep problems during the COVID-19 pandemic. Excessive daytime sleepiness because of the varied bedtime schedules is also one of the major causes of Hypersomnia. Thus, there is an increasing demand for the Hypersomnia treatment market to prevent further sleep disorders that arise due to COVID 19.
The Sleep Foundation (a Onecare Media Company), in its March 2022 article on ‘Sleep Guidelines During the COVID-19 Pandemic’, described the various factors associated with the sleep disorders during COVID-19, which included Infection and COVID-19, Disruption of Daily Life, Caregiving, Excess Screen Time, Anxiety and Worry, Depression and Isolation, Stress and Stress-Related Fatigue and Altered Dreams. According to an article published in December 2021 in the Egyptian Journal of Neurology, Psychiatry, and Neurosurgery, post-COVID-19 sleep disturbances were commonly reported in the recovery period. Also, these sleep deficits had an impact on the physical and mental aspects of quality of life.
The increased diagnosis of Hypersomnia cases is a major driver which is anticipated to boost the growth of the market. Several organizations, such as the National Center on Sleep Disorders Research, have advocated the need to address the growing concern. In 2020, according to the Cigna Health and Life Insurance Company’s (CHLIC) April 2020 article, it was observed that the sale of sleep disorder prescriptions increased by 14.8% from February 16 to March 15 of the year compared to the same period in 2019. The surge in the development of pipeline drugs and the increase in lifestyle diseases, especially anxiety and depression, are expected to propel the growth of the market in the forecast period. However, the side effect of the sleep disorder drugs is expected to limit the growth of the market.
The onset of the COVID lockdown has instigated an outbreak of several sleep disorders, notably hypersomnia. Significant discoveries in the treatment of Hypersomnia treatment and approval of novel drugs are expected to increase the Hypersomnia treatment market. The most commonly used medication for the treatment of hypersomnia is stimulants. According to an article published in the CNS Drugs in January 2020, stimulants used to treat hypersomnia are aimed at improving wakefulness and treating the symptoms of disturbed nocturnal sleep and sleep paralysis. One of the widely used stimulants for narcolepsy treatment is modafinil. Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. As per an article published in July 2020 in the journal Drugs in Context, modafinil was confirmed as the most extensively studied stimulant, characterized by a significant improvement in excessive daytime sleepiness (based on the Epworth Sleepiness Scale and Maintenance of Wakefulness Test) and an acceptable safety profile.
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor stimulant drug, is a newer class of stimulants currently being prescribed for the treatment of hypersomnia. According to an article published in the Nature and Science of Sleep journal in January 2021, Solriamfetol is the principal therapy for excessive sleepiness in obstructive sleep apnea or narcolepsy, either as initial or replacement or add-on therapy. The article also showed that the clinical trials had demonstrated short-term and long-term efficacy in decreasing propensity to sleep, promoting wakefulness, and improving quality of life. Solriamfetol has a good safety profile and acceptable side effects.
Raising awareness among people in recent times has led to the boost of hypersomnia diagnoses. The stimulants segment is likely to hold the major share in the forecast period due to the surge in the treatment of hypersomnia.
The increase in awareness among people and the growth in R&D are expected to boost the growth of the market in the North American region. Also, the increasing prevalence of lifestyle-related diseases among people in the United States is expected to drive the demand for the Hypersomnia treatment market in this region. According to the National Sleep Foundation’s Sleep in America poll, the Sleep Health Index for the last quarter of 2021 was 77 out of 100, which has been almost the same average result since 2016. The poll also depicted that various factors concerning the population in the USA, such as light exposure, screen use, mealtime consistency, physical activity, health, and stress, affected the sleep quality and patterns in the United States.
As per the Narcolepsy Factsheet published in November 2021 by the National Institute of Neurological Disorders and Stroke (NINDS), it was estimated that around 135,000 to 200,000 people in the United States have narcolepsy. However, the numbers may be much higher since the condition is often undiagnosed. The NINDS, along with other research institutes such as the National Center on Sleep Disorders Research (NCSDR), have been studying narcolepsy and other sleep-related disorders through the monitoring of genetic and biochemicals, immune system, and sleep biology. The National Center on Sleep Disorders Research has formulated the 2021 National Institute of Health Sleep Research Plan to advance the science of sleep and circadian research. Based on the scientific recommendations from the Sleep Disorders Research Advisory Board (SDRAB) and the NIH Sleep Research Coordinating Committee (SRCC), the plan advocates five strategic goals, research priorities, and tactics, along with the nine critical opportunities that help broaden the landscape of biomedical sciences in the context of sleep and circadian research.
This rise in the awareness of sleep disorders led to the approval and launch of novel drugs for Hypersomnia treatment. Thus the increasing awareness about the importance of Hypersomnia coupled with increasing investment in the health care department is known to propel the growth of the market in this region.
The Hypersomnia treatment market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Takeda pharmaceutical company Ltd., Teva pharmaceuticals Ltd., Jazz pharmaceuticals Ltd., Bioprojet, Avedal pharmaceuticals Plc., Pfizer Inc., Theranexus, Merck and Co., and others.
This product will be delivered within 2 business days.
Since the COVID-19 pandemic, the proportion of sleeping disorder complaints has risen drastically. The sleep disorders were characterized as intrinsic (arising from the body), extrinsic (due to environmental conditions), or disturbances to circadian rhythm. The social isolation and interruption of daily routines during the COVID 19 lockdown have caused a rise in psychological stress among people, which in turn has increased sleep disorders all over the world. An article presented in the Journal of Clinical Sleep Medicine in February 2021 deduced that around 40% of the people from the general and health care populations had reported various sleep problems during the COVID-19 pandemic. Excessive daytime sleepiness because of the varied bedtime schedules is also one of the major causes of Hypersomnia. Thus, there is an increasing demand for the Hypersomnia treatment market to prevent further sleep disorders that arise due to COVID 19.
The Sleep Foundation (a Onecare Media Company), in its March 2022 article on ‘Sleep Guidelines During the COVID-19 Pandemic’, described the various factors associated with the sleep disorders during COVID-19, which included Infection and COVID-19, Disruption of Daily Life, Caregiving, Excess Screen Time, Anxiety and Worry, Depression and Isolation, Stress and Stress-Related Fatigue and Altered Dreams. According to an article published in December 2021 in the Egyptian Journal of Neurology, Psychiatry, and Neurosurgery, post-COVID-19 sleep disturbances were commonly reported in the recovery period. Also, these sleep deficits had an impact on the physical and mental aspects of quality of life.
The increased diagnosis of Hypersomnia cases is a major driver which is anticipated to boost the growth of the market. Several organizations, such as the National Center on Sleep Disorders Research, have advocated the need to address the growing concern. In 2020, according to the Cigna Health and Life Insurance Company’s (CHLIC) April 2020 article, it was observed that the sale of sleep disorder prescriptions increased by 14.8% from February 16 to March 15 of the year compared to the same period in 2019. The surge in the development of pipeline drugs and the increase in lifestyle diseases, especially anxiety and depression, are expected to propel the growth of the market in the forecast period. However, the side effect of the sleep disorder drugs is expected to limit the growth of the market.
Key Market Trends
The Stimulants Segment is Expected to Hold a Major Market Share in the Hypersomnia treatment Market
The onset of the COVID lockdown has instigated an outbreak of several sleep disorders, notably hypersomnia. Significant discoveries in the treatment of Hypersomnia treatment and approval of novel drugs are expected to increase the Hypersomnia treatment market. The most commonly used medication for the treatment of hypersomnia is stimulants. According to an article published in the CNS Drugs in January 2020, stimulants used to treat hypersomnia are aimed at improving wakefulness and treating the symptoms of disturbed nocturnal sleep and sleep paralysis. One of the widely used stimulants for narcolepsy treatment is modafinil. Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. As per an article published in July 2020 in the journal Drugs in Context, modafinil was confirmed as the most extensively studied stimulant, characterized by a significant improvement in excessive daytime sleepiness (based on the Epworth Sleepiness Scale and Maintenance of Wakefulness Test) and an acceptable safety profile.
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor stimulant drug, is a newer class of stimulants currently being prescribed for the treatment of hypersomnia. According to an article published in the Nature and Science of Sleep journal in January 2021, Solriamfetol is the principal therapy for excessive sleepiness in obstructive sleep apnea or narcolepsy, either as initial or replacement or add-on therapy. The article also showed that the clinical trials had demonstrated short-term and long-term efficacy in decreasing propensity to sleep, promoting wakefulness, and improving quality of life. Solriamfetol has a good safety profile and acceptable side effects.
Raising awareness among people in recent times has led to the boost of hypersomnia diagnoses. The stimulants segment is likely to hold the major share in the forecast period due to the surge in the treatment of hypersomnia.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.
The increase in awareness among people and the growth in R&D are expected to boost the growth of the market in the North American region. Also, the increasing prevalence of lifestyle-related diseases among people in the United States is expected to drive the demand for the Hypersomnia treatment market in this region. According to the National Sleep Foundation’s Sleep in America poll, the Sleep Health Index for the last quarter of 2021 was 77 out of 100, which has been almost the same average result since 2016. The poll also depicted that various factors concerning the population in the USA, such as light exposure, screen use, mealtime consistency, physical activity, health, and stress, affected the sleep quality and patterns in the United States.
As per the Narcolepsy Factsheet published in November 2021 by the National Institute of Neurological Disorders and Stroke (NINDS), it was estimated that around 135,000 to 200,000 people in the United States have narcolepsy. However, the numbers may be much higher since the condition is often undiagnosed. The NINDS, along with other research institutes such as the National Center on Sleep Disorders Research (NCSDR), have been studying narcolepsy and other sleep-related disorders through the monitoring of genetic and biochemicals, immune system, and sleep biology. The National Center on Sleep Disorders Research has formulated the 2021 National Institute of Health Sleep Research Plan to advance the science of sleep and circadian research. Based on the scientific recommendations from the Sleep Disorders Research Advisory Board (SDRAB) and the NIH Sleep Research Coordinating Committee (SRCC), the plan advocates five strategic goals, research priorities, and tactics, along with the nine critical opportunities that help broaden the landscape of biomedical sciences in the context of sleep and circadian research.
This rise in the awareness of sleep disorders led to the approval and launch of novel drugs for Hypersomnia treatment. Thus the increasing awareness about the importance of Hypersomnia coupled with increasing investment in the health care department is known to propel the growth of the market in this region.
Competitive Landscape
The Hypersomnia treatment market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Takeda pharmaceutical company Ltd., Teva pharmaceuticals Ltd., Jazz pharmaceuticals Ltd., Bioprojet, Avedal pharmaceuticals Plc., Pfizer Inc., Theranexus, Merck and Co., and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Takeda pharmaceutical company Ltd.
- Teva pharmaceuticals Ltd.
- Jazz pharmaceuticals Ltd.
- Bioprojet
- Avedal pharmaceuticals Plc.
- Pfizer Inc.
- Theranexus
- Merck and Co.
Methodology
LOADING...
